- Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
admin Fri, 03/05/2021 - 16:42
Galderma announced a European re-launch of Sculptra® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients. Sculptra® can now be used immediately following a two-minute reconstitution and with the optional addition of lidocaine for patient comfort. Previously, healthcare professionals had to wait two hours following reconstitution to administer the product.
- US court decision favours Astrazeneca's Symbicort in patent litigation
admin Thu, 03/04/2021 - 15:37
The US District Court for the Northern District of West Virginia has decided in favour of AstraZeneca in litigation against Mylan Pharmaceuticals Inc. (Mylan) and Kindeva Drug Delivery L.P. (Kindeva), determining that asserted claims in three of AstraZeneca’s patents protecting Symbicort (budesonide/formoterol) in the US are not invalid.
- GSK and Vir Biotech COVID19 vaccine met initial pre-specified criteria in clinical trial
admin Thu, 03/04/2021 - 15:26
Vir Biotechnology, Inc and GlaxoSmithKline plc provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. The companies were informed that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the ACTIV-3 trial and there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.
- Pharmaron Acquires State of the Art Biomanufacturing Site in the UK from AbbVie
admin Wed, 03/03/2021 - 16:09
Pharmaron Beijing Co., Limited announced that it has entered into a definitive agreement to acquire Allergan Biologics Limited in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions.
- FDA Authorizes First Robotically-Assisted Surgical Device for Performing Transvaginal Hysterectomy
admin Tue, 03/02/2021 - 16:04
The U.S. Food and Drug Administration has authorized marketing of the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients. The Hominis Surgical System is intended for benign hysterectomy (removal of the uterus for non-cancerous conditions) with salpingo-oophorectomy (removal of one or both fallopian tubes and ovaries).
- Atherosclerosis can accelerate the development of clonal hematopoiesis : Study
admin Mon, 03/01/2021 - 15:53
Billions of peripheral white blood cells are produced every day by the regular divisions of hematopoietic stem cells and their descendants in the bone marrow. Under normal circumstances, thousands of stem cells contribute progeny to the blood at any given time, making white blood cells a group with diverse ancestry.
- AI based system predicts the onset of Alzheimer's Disease
admin Mon, 03/01/2021 - 15:42
Korea Brain Research Institute (KBRI, President Suh Pann-ghill) announced that the research team led by Dr. Jae-Yeol Joo discovered new cryptic splice variants and SNVs in PLCg1 gene of AD-specific models for the first time using Splice-AI.
This research outcome was published in PNAS, a world-renowned academic journal.
- Cancer cells waste so much energy, Why?
admin Mon, 03/01/2021 - 15:36
In the 1920s, German chemist Otto Warburg discovered that cancer cells don’t metabolize sugar the same way that healthy cells usually do. Since then, scientists have tried to figure out why cancer cells use this alternative pathway, which is much less efficient.
- Johnson and Johnson Covid-19 Vaccine receives FDA Nod for Emergency Use
admin Mon, 03/01/2021 - 15:19
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.
- Catalent to Acquire Delphi Genetics
admin Fri, 02/26/2021 - 15:49
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.